Skip to main content

Advertisement

Log in

Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group

  • Sarcoma
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

A Correction to this article was published on 17 March 2022

This article has been updated

Abstract

Background

Multi-visceral resection often is used in the treatment of retroperitoneal sarcoma (RPS). The morbidity after distal pancreatectomy for primary pancreatic cancer is well-documented, but the outcomes after distal pancreatectomy for primary RPS are not. This study aimed to evaluate morbidity and oncologic outcomes after distal pancreatectomy for primary RPS.

Methods

In this study, 26 sarcoma centers that are members of the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) retrospectively identified consecutive patients who underwent distal pancreatectomy for primary RPS from 2008 to 2017. The outcomes measured were 90-day severe complications (Clavien-Dindo ≥ 3), postoperative pancreatic fistula (POPF) rate, and oncologic outcomes.

Results

Between 2008 and 2017, 280 patients underwent distal pancreatectomy for primary RPS. The median tumor size was 25 cm, and the median number of organs resected, including the pancreas, was three. In 96% of the operations, R0/R1 resection was achieved. The 90-day severe complication rate was 40 %. The grades B and C POPF complication rates were respectively 19% and 5% and not associated with worse overall survival. Administration of preoperative radiation and factors to mitigate POPF did not have an impact on the risk for the development of a POPF. The RPS invaded the pancreas in 38% of the patients, and local recurrence was doubled for the patients who had a microscopic, positive pancreas margin (hazard ratio, 2.0; p = 0.042).

Conclusion

Distal pancreatectomy for primary RPS has acceptable morbidity and oncologic outcomes and is a reasonable approach to facilitate complete tumor resection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Change history

References

  1. Kleeff J, et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg. 2007;245:573–82.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lillemoe KD, et al. Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg. 1999;229:693–8; discussion 698–700.

  3. Reeh M, et al. High surgical morbidity following distal pancreatectomy: still an unsolved problem. World J Surg. 2011;35:1110–7.

    Article  PubMed  Google Scholar 

  4. Ecker BL, et al. Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy: analysis of 2026 resections from the International, Multi-institutional Distal Pancreatectomy Study Group. Ann Surg. 2019;269:143–9.

    Article  PubMed  Google Scholar 

  5. Gronchi A, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the Multi-Institutional Collaborative RPS Working Group. Ann Surg. 2016;263:1002–9.

    Article  PubMed  Google Scholar 

  6. Tseng WW, Pollock RE, Gronchi A. The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): “red wine or white”? Ann Surg Oncol. 2016;23:4418–20.

    Article  PubMed  Google Scholar 

  7. MacNeill AJ, et al. Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group. Ann Surg. 2018;267:959–64.

    Article  PubMed  Google Scholar 

  8. Trans-Atlantic Retroperitoneal Sarcoma Working Group. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol. 2018;29:857–71.

    Article  Google Scholar 

  9. van Houdt WJ, et al. New research strategies in retroperitoneal sarcoma: the case of TARPSWG, STRASS, and RESAR: making progress through collaboration. Curr Opin Oncol. 2019;31:310–6.

    Article  PubMed  Google Scholar 

  10. Raut CP, et al. Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG. Clin Cancer Res. 2019;25:2664–71.

    Article  PubMed  Google Scholar 

  11. Haas RLM, et al. Radiotherapy for retroperitoneal liposarcoma: a report from the Transatlantic Retroperitoneal Sarcoma Working Group. Cancer. 2019;125:1290–300.

    Article  CAS  PubMed  Google Scholar 

  12. Bassi C, et al. (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.

    Article  PubMed  Google Scholar 

  13. Keung EZ, et al. Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. Am J Surg. 2020;220:140–6.

    Article  PubMed  Google Scholar 

  14. Miao Y, et al. Management of the pancreatic transection plane after left (distal) pancreatectomy: expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2020.

  15. Fairweather M, et al. Incidence and adverse prognostic implications of histopathologic organ invasion in primary retroperitoneal sarcoma. J Am Coll Surg. 2017;224:876–83.

    Article  PubMed  Google Scholar 

  16. Toulmonde M, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors, and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014;25:735–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Berselli M, et al. Morbidity of left pancreatectomy when associated with multivisceral resection for abdominal mesenchymal neoplasms. JOP. 2011;12:138–44.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sanjay P. Bagaria MD.

Ethics declarations

Disclosure

Giovanni Grignani received grants from PharmaMar, Novartis, and Bayer and was a consultant for Novartis, Bayer, Pharmamar, EISAI, Lilly, and Merck. Piotr Rutkowski received honoraria from MSD, Bristol Myers Squibb, Novartis, Pierre Fabre, Amgen, Sanofi, Merck, Roche, and Blueprint Medicines. Sylvie Bonvalot received honoraria from Nanobiotix and Pharmamar. Nita Ahuja received funding from Astex on developing therapeutics for sarcomas.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Presented at the Society of Surgical Oncology, 2020, and the International Conference on Surgical Cancer Care, August 2020, Boston, MA, USA.

The original online version of this article was revised: Elisabetta Pennacchioli's affiliation was corrected.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 18 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bagaria, S.P., Swallow, C., Suraweera, H. et al. Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol 28, 6882–6889 (2021). https://doi.org/10.1245/s10434-021-09739-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-09739-9

Navigation